Cyclo Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Cyclo Therapeutics's estimated annual revenue is currently $2.2M per year.
- Cyclo Therapeutics's estimated revenue per employee is $100,500
Employee Data
- Cyclo Therapeutics has 22 Employees.
- Cyclo Therapeutics grew their employee count by 0% last year.
Cyclo Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Director Medical Affairs Europe | Reveal Email/Phone |
Cyclo Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $32.2M | 160 | N/A | N/A | N/A |
#2 | $15.1M | 75 | 23% | N/A | N/A |
#3 | $341.9M | 1701 | N/A | N/A | N/A |
#4 | $16.7M | 83 | 43% | N/A | N/A |
#5 | $10.9M | 54 | -4% | N/A | N/A |
#6 | $11.3M | 56 | -2% | N/A | N/A |
#7 | $211.7M | 1297 | 4% | N/A | N/A |
#8 | $29.1M | 145 | 5% | N/A | N/A |
#9 | $9.4M | 47 | -2% | N/A | N/A |
#10 | $11.9M | 59 | -8% | N/A | N/A |
What Is Cyclo Therapeutics?
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is conducting a Phase 2b clinical trial using Trappsol® Cyclo™ intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.
keywords:N/AN/A
Total Funding
22
Number of Employees
$2.2M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.2M | 22 | -4% | N/A |
#2 | $1.6M | 22 | -31% | N/A |
#3 | $3.8M | 22 | 0% | N/A |
#4 | $3.3M | 23 | -4% | N/A |
#5 | $3.2M | 23 | -8% | N/A |